Suzhou Zelgen Biopharmaceuticals Co.,ltd
Clinical trials sponsored by Suzhou Zelgen Biopharmaceuticals Co.,ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for tough cancers: experimental drug ZG006 enters human trials Results expected Sep 2026 (estimated)
- New hope for advanced cancer? experimental drug ZGGS18 enters human trials Results expected Nov 2026 (estimated)
- Healthy volunteers test two versions of experimental drug Results expected Feb 2027 (estimated)
- New drug duo targets tough lymphoma Results expected Apr 2027 (estimated)
- New combo aims to tackle lung cancer after immunotherapy fails Results expected Apr 2027 (estimated)
-
A shot to skip the misery of thyroid hormone withdrawal before cancer treatment?
Disease control CompletedThis phase 3 trial tests whether giving recombinant human thyrotropin (rhTSH) injections before radioactive iodine can effectively destroy leftover thyroid tissue after surgery for differentiated thyroid cancer. Normally, patients must stop thyroid hormone medication to raise TSH…
Phase 3 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Boosting thyroid cancer therapy: does rhTSH make radioactive iodine more effective?
Disease control CompletedThis phase 2 trial tests whether giving recombinant human thyroid stimulating hormone (rhTSH) before radioactive iodine can improve the destruction of leftover thyroid tissue after surgery in people with differentiated thyroid cancer. Participants receive either rhTSH injections …
Phase 2 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug ZGGS15 tested in patients with advanced cancers
Disease control CompletedThis early-stage trial tested a new biologic drug called ZGGS15 in 22 adults with advanced solid tumors who had no standard treatment options left. The main goals were to check safety, find the right dose, and look for early signs that the drug might control tumor growth. Partici…
Phase 1 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC